# A Novel Catheter for Thrombolytic Drug Infusion Therapy to treat Pulmonary Embolism

> **NIH NIH R43** · ONTOGEN MEDTECH LLC · 2022 · $258,793

## Abstract

PROJECT SUMMARY
 This SBIR Phase I project will focus on the development of a catheter specifically designed to reduce
bleeding complications from catheter-directed thrombolysis (CDT) treatment of pulmonary embolism (PE). PE
represents a leading cause of morbidity in the United States, with as many as 900,000 cases per year in the
United States alone. One in four patients with PE will die suddenly without warning, and PE is the third most
common cause of cardiovascular death. In addition, blood clots represent a significant burden on the economy,
with healthcare costs accounting for up to $10 billion dollars annually.
 CDT involves placing one or more small catheters directly within the blood clot(s) in the lung(s) and
infusing a thrombolytic medication (e.g. tissue plasminogen activator) to dissolve the clots over a 2-24 hour
time period. It is preferred over a peripheral intravenous bolus administration of tPA in all but the highest risk
patients, as a slower, more controlled infusion correlates with lower rates of life-threatening bleeding.
 While CDT-based thrombolytic infusions can be immensely effective, this therapy carries the risk of
major adverse events including catastrophic intracranial, vascular, or intra-abdominal bleeding, and the risk of
bleeding complications is proportional to the dose and duration of thrombolytic infusion. To minimize
this risk, the lowest possible dose of thrombolytic should be infused over the shortest duration. This ideal
endpoint would be the point when complete lysis occurs and any added thrombolytic only increases risk
without any therapeutic benefit. To date, no existing CDT device allows for personalized treatment and
real time monitoring of lytic effectiveness to allow for judicious titration of thrombolytic administration.
Customer discovery revealed that providers desire pressure data to inform treatment decision-making.
 The proposed device is a CDT catheter which minimizes the dose of thrombolytic delivered. It does this
by enabling hemodynamic monitoring across a thrombus for real-time detection of thrombus disruption,
AND by deploying expanding nitinol lytic “baskets” for maximized thrombolytic contact area with thrombi. Its
all-in-one design makes the procedure easier, safer, and less costly for the hospital.
 This catheter comprises two telescoping catheters wherein the outer catheter can be translated to
selectively expose preformed nitinol tubing baskets for adjustable-length three-dimensional lytic infusion.
The combined catheter system has four ports, each designed to address CDT milestones. The device will
allow the user to (1) precisely steer the catheter and sub-select a target branch, (2) perform high pressure
contrast injections to obtain diagnostic-quality angiograms, (3) infuse lytic in the full three-dimensional space of
the vessel to precisely fit and fully saturate the thrombus, and (4) measure real-time, continuous, simultaneous,
fluid-filled pressure proximal and distal to a thr...

## Key facts

- **NIH application ID:** 10547235
- **Project number:** 1R43HL164224-01A1
- **Recipient organization:** ONTOGEN MEDTECH LLC
- **Principal Investigator:** Tyler Panian
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $258,793
- **Award type:** 1
- **Project period:** 2022-09-10 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10547235

## Citation

> US National Institutes of Health, RePORTER application 10547235, A Novel Catheter for Thrombolytic Drug Infusion Therapy to treat Pulmonary Embolism (1R43HL164224-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10547235. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*